Procarbazine Production Cost Reports

The report provides a detailed analysis essential for establishing a procarbazine production plant. It encompasses all critical aspects necessary for procarbazine production, including the cost of procarbazine production, procarbazine plant cost, procarbazine production costs, and the overall procarbazine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a procarbazine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Procarbazine is an oral alkylating agent chemotherapy drug that inhibits DNA, RNA, and protein synthesis in cancer cells. It is used in combination regimens for advanced Hodgkin lymphoma as well as malignant brain tumours like glioblastoma multiforme, astrocytoma, oligodendrogliomas, and primary CNS lymphoma. It shows antitumor activity against various models, including lymphomas, leukaemia, and sarcomas. It is less commonly applied to non-Hodgkin lymphoma, soft tissue sarcoma, or investigational uses in other cancers like prostate or sickle cell-related complications. Its dosing is typically adjusted for organ function, taken with food to minimise nausea, and requires MAO inhibitor precautions due to interactions with tyramine-rich foods, alcohol, and sympathomimetics.

The market for procarbazine is driven by growth in the niche oncology segment. The sustained demand for Hodgkin lymphoma and brain tumour treatments like MOPP or PCV regimens boosts the market. The rising global cancer cases, along with improving oncology infrastructure fuels its market.

The heightened awareness of chemotherapy options and ongoing clinical trials exploring expanded applications expands its applications. The industrial procarbazine procurement is driven by its status as a mature generic with few dominant suppliers. The low raw material costs enabling affordable API production, strict GMP and oncology-specific quality controls, including stability for oral capsules, boost its market dynamics. The regulatory approvals with minimal barriers post-patent expiry, price stability favouring bulk hospital tenders and public health programs, etc. impacts its sourcing.

Raw Material for Procarbazine Production

According to the procarbazine production plant project report, the key raw materials used in the production of procarbazine include p-tolualdehyde, dibromo cyanuric acid, isopropylamine, N-bromosuccinimide, and methyl hydrazinium sulfate.

Production Process of Procarbazine

The extensive procarbazine production cost report consists of the following major industrial production process:

1. From p-Tolualdehyde: The production process of procarbazine starts from p-tolualdehyde, which reacts with dibromo cyanuric acid and isopropylamine. The reaction takes place at room temperature to form toluyl isopropylamine. This goes through side-chain bromination with N-bromosuccinimide under reflux, followed by hydrolysis in acetonitrile to yield formoxyl benzoyl isopropylamine. Finally, reductive amination with methyl hydrazinium sulfate and sodium cyanoborohydride in the presence of triethylamine produces procarbazine.

Procarbazine, an alkylating agent chemotherapy drug, has the molecular formula C12H19N3O with a molecular weight of 221.30 g/mol. It appears as a white to pale yellow solid or crystalline powder with a melting point around 223 degree Celsius. It has moderate water solubility and is chemically characterised by an N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide structure. It features a hydrazine moiety enabling DNA methylation at guanine O-6 positions. It has 4 hydrogen bond donors, 3 acceptors, 5 rotatable bonds and a topological polar surface area of 53.2 Ų. It has a complexity of 210, supporting its oral bioavailability and reactivity as a prodrug metabolised to alkylating species.